A first-in-class small molecule KAN0439834, active against ROR1 was selected as a lead candidate following an extensive drug development process including an HTS campaign against a recombinant intracellular part of ROR1 and subsequent optimization by phenotypic screening using CLL cells. Here, ROR1 is linked to B-cell chronic lymphocytic leukemia.